Babcock University Medical Journal (Dec 2023)

Anti-craving Property of Chlorpromazine in Pentazocine addiction among sickle cell disease patients: A Case Series

  • JOSHUA FALADE,
  • Patrick Olarewaju Osho,
  • Akindele Amos Ajayi,
  • Ayodeji Oluwaseun Ogungbemi,
  • Recheal Folashade Dare,
  • Akinwumi Ayodele Akinnuoye,
  • Sunday Sajo

DOI
https://doi.org/10.38029/babcockuniv.med.j..v6i2.182
Journal volume & issue
Vol. 6, no. 2

Abstract

Read online

Background: Opioids are useful in the management of vaso-occlusive crisis among Sickle Cell Disease patients; however, there is a need to search for drugs that can ameliorate the withdrawal symptoms without causing further dependence. Case presentations: Three patients living with Sickle cell disease abusing Pentazocine were managed with Tab Chlorpromazine 100mg twice daily for three weeks and had a significant reduction in the level of craving and also experienced improved sleep. Chlorpromazine demonstrates a high affinity for dopamine (DA) receptors and acts as a receptor antagonist by inhibiting adenylate cyclase activity. Conclusion: Chlorpromazine was found to be useful in the management of cravings associated with Pentazocine addiction.

Keywords